580 related articles for article (PubMed ID: 32639661)
21. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
22. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
23. BRCA mutations in pancreatic cancer and progress in their targeting.
Alkassis S; Yazdanpanah O; Philip PA
Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
[No Abstract] [Full Text] [Related]
24. Kub5-Hera
Motea EA; Fattah FJ; Xiao L; Girard L; Rommel A; Morales JC; Patidar P; Zhou Y; Porter A; Xie Y; Minna JD; Boothman DA
Clin Cancer Res; 2018 Dec; 24(24):6459-6470. PubMed ID: 30108102
[TBL] [Abstract][Full Text] [Related]
25. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
Wéra AC; Lobbens A; Stoyanov M; Lucas S; Michiels C
Cell Cycle; 2019 Aug; 18(15):1770-1783. PubMed ID: 31238782
[TBL] [Abstract][Full Text] [Related]
26. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
28. Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors.
Golan T; Raitses-Gurevich M; Beller T; Carroll J; Brody JR
Cancer Treat Res; 2023; 186():125-142. PubMed ID: 37978134
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of PARP: Number crunching and structure gazing.
Rudolph J; Jung K; Luger K
Proc Natl Acad Sci U S A; 2022 Mar; 119(11):e2121979119. PubMed ID: 35259019
[TBL] [Abstract][Full Text] [Related]
30. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
32. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
33. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
34. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Predisposition Genes and Synthetic Lethality.
Neiger HE; Siegler EL; Shi Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
[No Abstract] [Full Text] [Related]
37. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
Rosen DB; Leung LY; Louie B; Cordeiro JA; Conroy A; Shapira I; Fields SZ; Cesano A; Hawtin RE
J Transl Med; 2014 Jun; 12():184. PubMed ID: 24965603
[TBL] [Abstract][Full Text] [Related]
38. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T
Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
[TBL] [Abstract][Full Text] [Related]
39. A Novel Mechanism to Induce BRCAness in Cancer Cells.
Cai C
Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350
[TBL] [Abstract][Full Text] [Related]
40. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
